Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Sunitinib Stories

2008-09-11 09:00:48

Argos Therapeutics has initiated a Phase IIa trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma. Approximately 50 subjects with advanced renal cell carcinoma (RCC) will be enrolled in the Phase IIa trial. The study will be conducted at up to 15 sites in North America. The primary study objective is to evaluate clinical activity of AGS-003 in combination with sunitinib, as defined by RECIST criteria. Secondary...

2008-09-10 18:00:08

By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives. Anna Wolfenden's open letter to Ms Hart calls for a swift decision to be made about the availability of drugs such as Sunitinib that are widely available for patients with kidney cancer in the United States and other countries but have failed to secure the recommendation of NHS bodies in...

2008-09-10 09:00:09

Argos Therapeutics today announced the initiation of a Phase 2a trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma (RCC). AGS-003 is a product of the Company's Arcelis(TM) technology, which is an immunotherapy platform for creating personalized, RNA-loaded, dendritic cell-based therapies perfectly matched to each patient's unique tumor burden. In vitro and animal model studies of the impact of sunitinib on the...

2008-09-09 00:00:26

Campaigners battling for a cancer victim have been told their case is not exceptional enough. Family and friends of Kay Hopkins, from Harriseahead, are fighting for NHS North Staffordshire to provide the kidney cancer drug Sutent, which has not been approved by the National Institute for Health and Clinical Excellence. They argue that Kay's is an exceptional case. Without the drug it is not safe to operate on her kidney tumour. The 70-year-old wife's supporters had written to NHS...

2008-09-08 18:00:09

Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008. Researchers will present results of several analyses evaluating the cost effectiveness of SUTENT(R) as first-line therapy in patients with metastatic renal cell carcinoma...

2008-09-05 06:00:23

Cancer drug developer Antisoma has started a Phase II study of AS1411 in metastatic renal cell carcinoma. The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days for up to two cycles. Efficacy measures in the trial include response rate, time to progression...

2008-09-05 06:00:22

By LYNDSAY MOSS HEALTH CORRESPONDENT PATIENTS should be allowed to pay privately for cancer drugs and still keep their free NHS care in certain cases, the Scottish Government indicated yesterday. So-called co-payments - patients topping up their care with treatments not available on the NHS - have been banned by many Scottish health boards. But the government has now admitted current guidance on the controversial issue is not clear and has agreed to give new advice to the NHS. It...

2008-09-04 03:00:25

London, UK: 04 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer). The single-arm trial will enrol around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days...

2008-08-26 18:00:48

By Emma Brady Midlands cancer patients are being kept in the dark about new treatments that could extend their lives, it was claimed today. One in four myeloma specialists questioned in a survey admitted hiding facts about new treatments that may be tough to obtain on the NHS, citing the main reason was to avoid upsetting or confusing patients. The Myeloma UK poll comes less than three weeks after the National Institute for health and Clinical Excellence (Nice) issued draft guidance...

2008-08-25 09:00:26

Leading UK cancer experts have accused a health watchdog of forcing patients to remortgage their homes to afford treatments freely available in Europe. The group of 26 professors were "dismayed" at guidance issued by the National Institute for Health and Clinical Excellence (Nice) to deny patients four vital kidney cancer drugs on the NHS. They said the decision showed it was time for a "radical change" in how the NHS makes decisions on what treatments are available for cancer sufferers....